Got questions about one day NGS? Book an on-site meeting.
At Thermo Fisher Scientific, we are powering the future of molecular testing and clinical trials.
Together, our global network and advanced next-generation sequencing (NGS) solutions are helping to advance both myeloid and lymphoid malignancy research.
Meet us at ASH to explore our comprehensive hemato-oncology research portfolio and take a tour of the Genexus, the only automated NGS platform that can deliver results in as little as 24 hours.
ASH 2024 Industry Theater
Date: Sunday December 8, 8:00-9:00 am PST
Location: Room 1A, Upper Level, San Diego Convention Center
Chris Allen
Sr. Medical Affairs Specialist
Thermo Fisher Scientific
Sophie Rozenzhak, PhD
Sr. Product Manager
Thermo Fisher Scientific
Meet with our colleagues at PPD, part of Thermo Fisher Scientific, to learn more about participating in oncology clinical trials.
Learn how the NCI myeloMATCH trial is using rapid NGS testing with the Ion Torrent Genexus System to help enable study enrollment within 72 hours for newly diagnosed AML and MDS patients.
NCI has validated Genexus for investigational use within the MyeloMatch study. Genexus is currently available in the North America for research use only. Not for use in diagnostic procedures.
Jerald Radich, MD
Professor, University of Washington School of Medicine, Member Clinical Research Division Kurt Enslein
Endowed Chair
Fred Hutchinson Cancer Research Center
On-Demand Webinars
In this workshop, see how rapid NGS is helping to facilitate swift patient enrollment into a clinical trial aiming to investigate the effectiveness of various therapeutic agents based on genetic testing results.
Also, learn how NGS technology is advancing measurable residual disease (MRD) analysis by detecting low‑frequency variants with high sensitivity across a broad number of genes simultaneously.
Cecilia Yeung, MD
Associate Professor
Fred Hutchinson Cancer Center
Medical Director,
Fred Hutch CLIA laboratories
See recent performance data for the NCI Myeloid Assay v2, showing high specificity, sensitivity, accuracy, and reproducibility (inter-lab and intra-lab) with sequencing results generated within 48 hours of assay initiation2. Read Abstract
> View Poster
A myeloid genomic profiling solution that can deliver an NGS report, covering key DNA and RNA targets, in as little as 1 day on the Ion Torrent Genexus System. Learn More
A DNA and RNA assay for comprehensive myeloid MRD analysis using highly sensitive AmpliSeq HD technology which enables a limit of detection as low as 0.05% allele frequency. Learn More
Advanced NGS solutions that can sequence multiple B- and T-cell receptor targets in a single reaction for highly sensitive and specific clone detection. Learn More
Profile a range of lymphoid mutations in a single test in as little as 24 hours and access a community network of leading researchers.
Meet with Us
to Learn More
The Ion Torrent™ Genexus™ System is the only turnkey next-generation sequencing (NGS) solution that automates the end-to-end workflow from the biological specimen all the way to the final report and delivers results in as little as a single day.*
Thinking about how the Genexus System works and how it could fit into your lab?
In our virtual laboratory environment powered by augmented reality (AR) technology, you can see:
